DAX19.323 +0,9%ESt504.789 +0,7%MSCIW3.765 +0,3%Dow44.243 +0,9%Nas18.997 +0,1%Bitcoin95.397 +1,4%Euro1,0412 -0,6%Öl75,20 +1,1%Gold2.708 +1,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 Bayer BAY001 Siemens Energy ENER6Y EVOTEC 566480 Volkswagen (VW) vz. 766403 Amazon 906866 Deutsche Telekom 555750 NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000 Coinbase A2QP7J Deutsche Bank 514000 Palantir A2QA4J
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen in der Gewinnzone -- DAX geht deutlich fester ins Wochenende -- Bitcoin knapp vor 100.000 US-Dollar -- Chef der US-Börsenaufsicht tritt ab -- RWE, Secunet, NEL im Fokus
Top News
Diese Aktien empfehlen Experten zu kaufen Diese Aktien empfehlen Experten zu kaufen
Ölpreis, Holzpreis, Silberpreis & Co.: Wie sich die Rohstoffe am Abend entwickeln Ölpreis, Holzpreis, Silberpreis & Co.: Wie sich die Rohstoffe am Abend entwickeln
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Medincell Aktie

NeuKaufenVerkaufen
16,90 EUR ±0,00 EUR ±0,00 %
FSE
17,16 EUR -0,04 EUR -0,23 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.502,67 Mio. EUR

Div. Rendite0,00%

WKNA2N6VA

ISINFR0004065605

SymbolMDCLF

Medincell Aktien News

DatumMeistgelesen
BusinesswireMedincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
BusinesswireMedincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
BusinesswireMedincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia
Wer­bungMedincell-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireMedincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
BusinesswireMedincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
BusinesswireMedincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline
BusinesswireMedincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress
BusinesswireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
BusinesswireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
BusinesswireUnitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
BusinesswireMedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)
BusinesswireMedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
BusinesswireMedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
BusinesswireMedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement
BusinesswireMedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
BusinesswireInitiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
BusinesswireMedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
BusinesswireAdditional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
BusinesswireFrance : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments
BusinesswireMedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
BusinesswireMedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission
BusinesswireMedinCell Secures Additional 20 Million Euros Financing With the European Investment Bank (EIB)
BusinesswirePhase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology
BusinesswireAn Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report
BusinesswireMedinCell: US Pharma Development Expert Richard Malamut, MD Becomes Chief Medical Officer
BusinesswireMedinCell’s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM
BusinesswireMedinCell provides additional information regarding the new drug application for MDC-IRM
BusinesswireMedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE

Medincell News

Medincell News: auf dieser Seite finden Sie alle Medincell News und Nachrichten zur Medincell Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Medincell News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Medincell News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.